…
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Sotera Health provides sterilization and laboratory testing services for medical device, pharmaceutical and healthcare customers through businesses such as Sterigenics and Nelson Labs. Long-term growth may be supported by rising global demand for medical products, continued outsourcing of complex sterilization and testing, and regulatory focus on product safety, which could support recurring revenue and utilization trends.
Key investment risks include regulatory and environmental scrutiny of ethylene oxide operations, potential plant shutdowns or remediation costs, operational concentration in sterilization technologies and related execution risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -243.11M | 175.72M | -38.86M | -0.92M | 24.22M |
| Minority interest | 0.00M | -0.24M | 15.90M | 15.07M | 14.76M |
| Net income | -233.57M | 116.88M | -37.49M | -20.43M | -5.87M |
| Selling general administrative | 245.71M | 198.16M | 178.53M | 147.48M | 133.36M |
| Gross profit | 557.00M | 518.67M | 443.57M | 395.43M | 357.25M |
| Reconciled depreciation | 145.55M | 63.78M | 143.56M | 146.72M | 146.82M |
| Ebit | 248.35M | 256.73M | 206.02M | 183.60M | 169.78M |
| Ebitda | 317.73M | 335.71M | 274.46M | 343.35M | 316.60M |
| Depreciation and amortization | 69.38M | 78.98M | 68.44M | 159.76M | 146.82M |
| Non operating income net other | - | -6.83M | - | - | - |
| Operating income | 248.35M | 256.73M | 206.02M | 183.60M | 80.85M |
| Other operating expenses | 755.34M | 674.75M | 612.14M | 588.94M | 580.24M |
| Interest expense | 80.14M | 74.19M | 215.26M | 157.73M | 143.33M |
| Tax provision | -9.54M | 58.59M | -1.37M | 19.51M | 30.10M |
| Net interest income | -80.14M | -74.19M | -215.26M | -157.73M | -143.33M |
| Income tax expense | -9.54M | 58.59M | -1.37M | 19.51M | 30.10M |
| Total revenue | 1003.69M | 931.48M | 818.16M | 778.33M | 746.15M |
| Total operating expenses | 308.65M | 261.94M | 237.55M | 206.04M | 191.34M |
| Cost of revenue | 446.68M | 412.81M | 374.59M | 382.90M | 388.90M |
| Total other income expense net | -491.46M | -81.02M | -244.88M | -184.51M | 1.63M |
| Net income from continuing ops | -233.57M | 117.12M | -37.49M | -20.43M | -5.88M |
| Net income applicable to common shares | -233.57M | 116.88M | -38.62M | -20.85M | -5.87M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3130.42M | 3117.70M | 2789.50M | 2761.28M | 2580.67M |
| Intangible assets | 416.32M | 491.26M | 598.84M | 643.37M | 696.01M |
| Other current assets | 28.09M | 93.09M | 76.57M | 86.73M | 10.44M |
| Total liab | 2686.69M | 2767.47M | 2203.41M | 2306.70M | 3221.81M |
| Total stockholder equity | 443.73M | 350.24M | 586.10M | 454.57M | -642.57M |
| Deferred long term liab | - | - | 134.50M | - | - |
| Other current liab | 126.62M | 498.89M | 69.17M | 71.59M | 60.74M |
| Common stock | 2.86M | 2.86M | 2.86M | 2.86M | 2.32M |
| Capital stock | 2.86M | 2.86M | 2.86M | 2.86M | 2.32M |
| Retained earnings | -654.44M | -705.82M | -472.25M | -589.13M | -550.51M |
| Other liab | - | 150.25M | 298.71M | 253.81M | 253.44M |
| Good will | 1111.19M | 1101.77M | 1120.32M | 1115.94M | 1035.87M |
| Other assets | - | 82.91M | 33.63M | 77.15M | 18.81M |
| Cash | 301.65M | 396.29M | 106.92M | 102.45M | 62.86M |
| Total current liabilities | 230.65M | 791.57M | 161.16M | 140.60M | 123.99M |
| Current deferred revenue | 13.49M | 12.14M | 8.67M | 6.06M | 3.63M |
| Net debt | 2025.40M | 1557.22M | 1636.61M | 1722.34M | 2785.51M |
| Short term debt | 19.50M | 206.40M | 10.45M | 10.56M | 17.62M |
| Short long term debt | 4.80M | 197.12M | - | - | 16.33M |
| Short long term debt total | 2327.06M | 1953.51M | 1743.53M | 1824.79M | 2848.38M |
| Other stockholder equity | 1188.00M | 1159.85M | 1139.05M | 1134.68M | -0.39M |
| Property plant equipment | - | 796.75M | 690.74M | 651.86M | 577.64M |
| Total current assets | 557.24M | 645.01M | 345.96M | 315.01M | 252.35M |
| Long term investments | - | 0.00M | 9.40M | 13.46M | - |
| Net tangible assets | - | -1242.80M | -1133.07M | -1307.00M | -2374.45M |
| Short term investments | 0.71M | - | - | 13.46M | - |
| Net receivables | 175.52M | 118.48M | 108.18M | 91.73M | 111.58M |
| Long term debt | 2223.67M | 1747.12M | 1743.53M | 1824.79M | 2800.87M |
| Inventory | 51.98M | 37.15M | 54.29M | 34.09M | 37.40M |
| Accounts payable | 71.04M | 74.14M | 72.87M | 52.40M | 42.00M |
| Accumulated other comprehensive income | -92.68M | -106.65M | -83.57M | -93.84M | -94.39M |
| Common stock total equity | - | - | 2.86M | 2.86M | 2.32M |
| Retained earnings total equity | - | - | -472.25M | - | - |
| Treasury stock | - | - | -33.55M | - | - |
| Non currrent assets other | 59.47M | 74.55M | 18.34M | 9.30M | 12.24M |
| Non current assets total | 2573.18M | 2472.70M | 2443.54M | 2446.26M | 2328.32M |
| Capital lease obligations | 98.58M | 87.81M | 84.34M | 84.44M | 31.17M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -181.90M | -159.83M | -158.69M | -57.26M | 96.64M |
| Change to liabilities | 1.11M | 31.09M | -6.02M | -8.97M | 15.12M |
| Total cashflows from investing activities | -181.90M | -159.83M | -158.69M | -57.26M | 96.64M |
| Net borrowings | 200.00M | -100.00M | -1027.33M | 583.52M | -14.63M |
| Total cash from financing activities | 197.76M | -117.29M | 73.43M | -126.03M | -191.86M |
| Change to operating activities | 418.57M | -12.59M | -3.36M | -3.09M | -5.87M |
| Net income | -233.57M | 117.12M | -37.49M | -20.43M | -5.88M |
| Change in cash | 289.37M | 4.47M | 39.43M | -33.76M | 20.67M |
| Begin period cash flow | 106.92M | 102.45M | 63.02M | 96.79M | 76.12M |
| End period cash flow | 396.29M | 106.92M | 102.45M | 63.02M | 96.79M |
| Total cash from operating activities | 277.96M | 281.55M | 120.58M | 149.04M | 119.56M |
| Issuance of capital stock | 0.00M | 0.00M | 1155.96M | - | - |
| Depreciation | 145.55M | 150.90M | 143.56M | 146.72M | 146.82M |
| Other cashflows from investing activities | 0.03M | -0.70M | -0.70M | -0.70M | 6.43M |
| Dividends paid | - | 0.00M | -150.00M | -691.17M | 175.84M |
| Change to inventory | 14.44M | -20.25M | 3.78M | -0.28M | -7.04M |
| Change to account receivables | -12.55M | -15.51M | 1.94M | 11.76M | -2.91M |
| Sale purchase of stock | -0.39M | -1.43M | -34.00M | - | - |
| Other cashflows from financing activities | 198.19M | -15.85M | 278.80M | 3126.22M | -1.38M |
| Change to netincome | -51.13M | 177.01M | 13.81M | 21.18M | -34.02M |
| Capital expenditures | 182.38M | 102.16M | 53.51M | 57.26M | 72.61M |
| Change receivables | - | -15.51M | - | - | - |
| Cash flows other operating | - | -7.93M | - | - | - |
| Cash and cash equivalents changes | - | 4.43M | - | - | - |
| Change in working capital | 409.23M | -12.59M | -11.79M | -8.35M | 4.04M |
| Stock based compensation | 21.21M | 13.87M | 10.99M | 6.88M | 6.94M |
| Other non cash items | 9.49M | 15.96M | 38.68M | 43.21M | 12.96M |
| Free cash flow | 95.58M | 179.38M | 67.08M | 91.78M | 46.95M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SHC Sotera Health Co |
-0.06 0.36% |
16.38 | 58.95 | 15.67 | 3.04 | 7.20 | 4.98 | 12.85 |
| TMO Thermo Fisher Scientific Inc |
-15.12 2.11% |
702.59 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-1.34 0.57% |
233.97 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
24.91 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.17 0.68% |
24.93 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
9100 South Hills Boulevard, Broadview Heights, OH, United States, 44147
440 262 1410
3000
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael B. Petras Jr. | Chairman & CEO | 1969 |
| Mr. Michael P. Rutz | Pres of Sterigenics | 1971 |
| Mr. Michael F. Biehl | Interim Chief Financial Officer | 1956 |
| Mr. Kevin Theriault | Sr. VP of Operations | NA |
| Mr. Robert G. Hauzie | Chief Information Officer | NA |
| Joseph Vitale | VP of Investor Relations | NA |
| Mr. Alexander Dimitrief | Sr. VP & Gen. Counsel | 1959 |
| Ms. Kristin A. Gibbs | Chief Marketing Officer | NA |
| Mr. William Lehmann Jr., J.D., M.B.A., MBA | Sr. VP of Strategy & Corp. Devel. | 1966 |
| Ms. Sally R. Turner | Chief HR Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.